A. Fredriksson et al., Effects of MAO inhibitors upon MPTP mice chronically treated with suprathreshold doses of L-dopa, BEHAV PHARM, 11(7-8), 2000, pp. 571-581
Groups of mice were administered either saline or 1-methyl-4-phenyl-1,2,3,6
-tetrahydropyridine (MPTP) (2 x 40 mg/kg, s.c., separated by a 24-hour inte
rval) 4-6 weeks prior to behavioural testing. At testing, all the MPTP-inje
cted mice were repeatedly administered L-dopa (20 mg/kg, s.c., five times e
ach week, Monday-Friday), by applying a procedure that induced a severe red
uction of motor activity parameters from Day 1 to Day 25. Control (uninject
ed mice) received only saline and were retained only fur neurochemical anal
ysis. In each of three experiments, following the reduction of the activity
-stimulating effects of L-dopa by repeated administration, a restorative ef
fect of different monoamine oxidase (MAO) inhibitors was tested by co-admin
istration of the test compounds (irreversible MAO-B inhibitor, reversible M
AO-A inhibitors, or irreversible MAO-A/mixed MAO inhibitors) with L-dopa (2
0 mg/kg). In each case the MAO inhibitor was injected 60 min prior to L-dop
a. L-Deprenyl (3 or 10 mg/kg, s.c.), in combination with L-dopa, reinstated
locomotion and total activity, but not rearing, dose-dependently, in L-dop
a-tolerant mice. The reversible MAO-A inhibitors, amiflamine acid alpha -et
hyltryptamine, in combination with L-dopa, reinstated locomotion and total
activity, leaving rearing unaffected; Ro 41-1049 (3 mg/kg, s.c.) restored a
ll three parameters of activity; locomotor activity was restored by all thr
ee doses (1, 3, and 10 mg/kg, s.c.). On the other hand, neither the irrever
sible MAO-A inhibitor, clorgyline, nor the mixed MAO inhibitor, phenelzine,
produced any directly effective restorative increments. Neurochemical anal
ysis confirmed the severe striatal dopamine depletion of MPTP-treated mice.
These results demonstrate a synergistic and restorative action of combinin
g certain MAO inhibitors, namely the reversible MAO-A inhibitors, with the
suprathreshold dose of L-dopa in MPTP-treated, L-dopa-tolerant mice. (C) 20
00 Lippincott Williams & Wilkins.